Evidence map›Paper›PMID 39447106›Full record

ArticleAmerican journal of public health2025

Prior Authorization Requirements and Medicaid Enrollees' Use of Tobacco Cessation Medications, Colorado, 2023.

Marcus Dillender, Robin Mermelstein

Abstract read
In one paragraph

Article in American journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marcus DillenderMarcus Dillender is with the Department of Economics, Vanderbilt University, Nashville, TN. Robin Mermelstein is with the Department of Psychology and the Institute for Health Research and Policy, University of Illinois at Chicago.ORCID 0000-0003-3838-2465
Robin MermelsteinMarcus Dillender is with the Department of Economics, Vanderbilt University, Nashville, TN. Robin Mermelstein is with the Department of Psychology and the Institute for Health Research and Policy, University of Illinois at Chicago.ORCID 0000-0002-8690-1074

Funding

Examining the Impact of Medicaid's Prior Authorization Requirements for Tobacco Cessation Medications on Tobacco Cessation Medication PrescriptionsR03CA270451 · NCI · VANDERBILT UNIVERSITY · PI DILLENDER, MARCUS OWEN · 2023 to 2024
$159k
NCI NIH HHS R03 CA270451
6 · The paper itself

Abstract

Despite tobacco cessation medications being a first-line treatment for quitting smoking, a majority of Medicaid programs require health care providers to obtain prior authorization before prescribing them. We examined the impact of Colorado's Medicaid program removing its prior authorization requirement for these drugs on their use and estimated the additional number of Coloradoans who used these therapies in 2023 because of the policy change. The findings indicate that these requirements decrease low-income people's use of these medications. (

Indexed as

MedicaidPrior AuthorizationAdultColoradoFemaleHumansMalePovertySmoking Cessation AgentsTobacco Use CessationUnited StatesSmoking Cessation Agents

Identifiers

PMID39447106
PMCPMC11628720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.